The abstract is read at the publisher; the summary is JClub's.
NRAS knockdown with a mutation-agnostic antisense oligonucleotide resensitizes gilteritinib-resistant FLT3-mutated AML cells across multiple NRAS mutations, reversing the monocytic state.
- Why it matters: Relapse after gilteritinib is rapid, and resistance is linked to NRAS mutations plus a shift toward monocytic differentiation, limiting durable responses.
- What they did: The authors used an NRAS-targeting ASO in resistant AML cell lines, in vivo cell line-derived xenografts, and primary patient samples, then profiled transcriptomics, proteomics, and phosphoproteomics.
- The result: NRAS depletion reversed monocytic phenotype and restored drug sensitivity, with efficacy independent of NRAS-mutant variant allele frequency, and it also resensitized venetoclax-resistant primary cells with NRAS mutations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.